12th ICML Highlights in Lymphoma

12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. Peter Borchmann discusses how discrimination of an early unfavorable risk group has significant impact on treatment outcome in early stage Hodgkin lymphoma.
12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. Robert Chen discusses the findings from his clinical trial with Brentuximab vedotin and reduced-intensity allogeneic transplant in relapsed or refractory Hodgkin lymphoma.
12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. Andrew Evens discusses clinical trials and comorbidities specific to the treatment of Hodgkin lymphoma in the elderly.
12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. Mary Gospodarowicz discusses if radiation therapy should be a part of the standard therapy for stage 1 and 2 Hodgkin lymphoma.
12th ICML Highlights in Lymphoma published on July 12, 2013
Prof. Tim Illidge discusses the role of radiation therapy in the treatment of Hodgkin lymphoma.
12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. Peter Johnson discusses the results from the international response adapted therapy in advanced HL (RATHL) study, responses and chemotherapy dose adjustment determined by PET-CT imaging.
12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. James Armitage discusses the latest updates in the treatment of Hodgkin lymphoma.
12th ICML Highlights in Lymphoma published on July 12, 2013
Dr. James Armitage provides an overview of the 12th International Conference on Malignant Lymphoma.

Results 1 - 8 of 8

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved